HONG KONG, Sept. 23, 2026 /PRNewswire/ -- Most healthcare AI tools can analyze symptoms and suggest a care plan, but far fewer can help patients follow through. The gap appears both when people try to maintain proper form during a home workout and when they must navigate an unfamiliar hospital in another language. This distance between digital advice and real-world action can be thought of as a "last-mile execution gap."
Bridging that gap requires more than standalone algorithms. Frost & Sullivan's 2026 Blue Book on the Development of the Global AI Healthcare Industry argues that medical AI is moving from isolated diagnostic tools toward integrated systems that combine data, medical knowledge and clinical workflows. In this model, value lies less in one-off efficiency gains than in redesigning the end-to-end care process and connecting the providers involved.
Ping An Good Doctor (HKEX: 1833), this Hong Kong-listed company is pairing AI models with an on-the-ground service network.
The gap is visible in home-based exercise and rehabilitation. People may know which exercises to do, but without real-time feedback they can perform them incorrectly, reducing their potential benefit or increasing the risk of injury.
A market forecast projects that the global market for AI personal trainers will grow from $16.9 billion in 2025 to $65.7 billion by 2033. In 2024, China's National Health Commission launched the "Weight Management Year" initiative, which is also putting exercise and weight management higher on the public-health agenda.
Ping An Good Doctor recently upgraded its Ping An AI Doctor service, offering Ping An Smart Private Coach. The company describes it as a hybrid solution combining AI guidance with coaching, designed to extend family health management beyond consultation and chronic-disease management to guided, at-home exercise and rehabilitation.
Using technology that tracks 34 points on the body, the service monitors movement and provides real-time feedback in seven categories, including posture correction, chronic-pain rehabilitation, postpartum recovery and Baduanjin, a traditional Chinese qigong exercise. Ping An AI Doctor can connect users to its wider service network, creating a care pathway that spans prevention, consultation, guided exercise and rehabilitation.
Cross-border care presents a similar last-mile problem. Language barriers and unfamiliar hospital procedures can delay care for international visitors and residents.
The launch of Ping An GlobalCare came as China expanded its visa-free entry policies. Ping An Good Doctor unveiled the platform at the Shenzhen Sci-Tech Innovation Exhibition. According to the government, entries by foreign nationals exceeded 60 million in the first eight months of 2026.
Now being piloted in Shenzhen, the platform supports registration with phone numbers issued in 198 countries and regions and includes an AI translation engine tuned for medical terminology in 19 languages.
The platform is designed to go beyond translation through an end-to-end care pathway: online assessment, case coordination and in-person assistance. In one company-reported case, a U.S. user with acute abdominal pain completed an online triage session supported by AI translation. A case coordinator then helped arrange transport and guided him through hospital registration and diagnostic tests; the company says the process was completed within three hours.
In both cases, the AI is not the endpoint but a trigger for a human or physical service.
These offerings are examples of Ping An Good Doctor's broader service model, which it describes as online, in-hospital, at-home and corporate health services. The company also says the AI ecosystem is supported by its proprietary multimodal model, Ping An Medical Master®.
According to Ping An Good Doctor's 2026 Interim Report, its "AI + Physician" collaboration mechanism covers 100% of Ping An Group's retail customers. The report also says that the company's AI business accounted for approximately 4.6% of gross profit in the first half of 2026.
Whether it is Ping An Smart Private Coach, which supports at-home fitness and rehabilitation, or Ping An GlobalCare, which helps users navigate cross-border care, these initiatives are concrete examples of the broader healthcare AI strategy being pursued by Ping An Good Doctor and its parent company, Ping An Insurance (Group) Company of China, Ltd.
The strategy is designed to make AI more than a source of medical insight. By connecting patients with doctors, hospitals and support services, it aims to enable a more connected, accessible and continuous care experience.
View original content:https://www.prnewswire.co.uk/news-releases/from-advice-to-action-how-ping-an-good-doctor-is-bringing-healthcare-ai-into-the-real-world-302887567.html
Roche versucht nach einer Phase von Forschungsrückschlägen und Belastungen durch auslaufende Patente, das Tempo in der Medikamentenentwicklung deutlich zu erhöhen. Am Pharma-Investorentag unterstrich die Pharmasparte des Basler Konzerns den Anspruch, in Forschung und Entwicklung weiter zur Spitzengruppe zu gehören. Zentral sind dabei ein strengeres Management der Pipeline, Effizienzprogramme und der verstärkte Einsatz künstlicher Intelligenz entlang der Wertschöpfungskette.
Pharma-Chefin Teresa Graham verwies auf eine sichtbar verbesserte Bilanz seit dem letzten „Pharma Day“: In zehn zulassungsrelevanten Studien habe Roche die gesetzten Ziele erreicht, sechs Programme seien in die zulassungsrelevende Phase vorgerückt, drei weitere in Phase II. Insgesamt verfügt Roche nach eigenen Angaben über bis zu 20 neue Wirkstoffe, die bis 2030 auf den Markt kommen könnten. Einzelne Kandidaten wie das Brustkrebsmittel Giredestrant traut der Konzern dabei jeweils Spitzenumsätze im zweistelligen Milliardenbereich zu.
Um diese Ambitionen abzusichern, verschärft Roche die internen Selektionskriterien. Ende 2023 führte der Konzern mit „The Bar“ einen neuen Bewertungsrahmen für die Pipeline ein. Nur Wirkstoffkandidaten, die klar definierte Anforderungen erfüllen, werden weiterentwickelt. Medizinchef Levi Garraway bezeichnete „The Bar“ als Leitbild für Forschung und Entwicklung. Die Auswahl potenzieller Projekte sei damit spürbar strenger geworden – mit dem Ziel, Ressourcen konsequent auf die Erfolg versprechendsten Programme zu konzentrieren und die Erfolgsquote in späten Studienphasen zu stabilisieren oder weiter zu erhöhen.
Parallel dazu treibt Roche ein Effizienzprogramm voran, um Mittel aus weniger renditestarken in wachstumsstärkere Projekte umzuschichten. Die Entwicklung neuer Medikamente soll deutlich beschleunigt werden, was insbesondere in umkämpften Indikationen wie Onkologie sowie in wachstumsstarken Bereichen wie Herz-Kreislauf- und Stoffwechselerkrankungen an Bedeutung gewinnt. Damit will Roche erwartete Umsatzeinbussen durch Patentabläufe mehr als kompensieren und sich bis zum Ende des Jahrzehnts ein Portfolio aufbauen, das von mehreren potenziellen Blockbustern getragen wird.